Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 4CNS 3Breast 2Tumor-Agnostic 1Sarcoma 1Genitourinary 1

Conditions

Breast Neoplasms 2

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Triiodothyronine × Breast × Clear all
NCT03787303 2022-05-13

B-TREUH

Aultman Health Foundation

Phase 2 Terminated
7 enrolled 14 charts
Breast

Breast Neoplasms

NCT01360177 2016-07-20

Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Stanford University

Phase NA Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡